The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COSTEM 2019 | Is MRD monitoring prior to allograft standard in AML?
Michael Heuser
• 25 Oct 2019
Michael Heuser, MD, Hannover Medical School, Hannover, Germany, talks on standard practice and measurable residual disease (MRD) monitoring prior to allograft in acute myeloid leukemia (AML). This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.
